fbpx

Category

Lundbeckfonden Emerge
Copenhagen, Denmark – January 13, 2020:  IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today that it has raised EUR 127 million in Series B financing. The financing round was led by HBM Healthcare Investments, and other new investors joining the round included Vivo Capital, Kurma...
12. January – (Image: IO Biotech) The Lundbeck Foundation increases its commitment to IO Biotech as part of our 2030 strategy The Lundbeck Foundation is joining forces with IO Biotech’s other current owners, Novo Holdings and Sunstone, to invest in a major new Series B financing round in this immune-oncology specialist that is attracting significant...
COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ — IO Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy IO102 and IO103 with anti-PD-1 mAb for patients with unresectable/ metastatic melanoma. IO102 and IO103 are IO Biotech’s lead immuno-oncology candidates. Both compounds are based on...
SAN DIEGO and COPENHAGEN, Denmark, Nov. 18, 2020 /PRNewswire/ — AFYX Therapeutics (“AFYX”), a clinical-stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced the appointment of Dennis D. Kim, M.D., MBA, as chief medical officer. Dr. Kim will lead the clinical development of Rivelin®-Clobetesol for the treatment of oral lichen planus, Rivelin®-Mometasone for...
Copenhagen, Oct. 2020   SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, today announced the appointment of Dr. Milan Zdravkovic, MD, PhD as Chief Medical Officer from 01 November 2020. Dr. Zdravkovic will lead SNIPR Biome’s development activities.   Before joining SNIPR Biome, Dr. Zdravkovic was most recently Chief Medical Officer and Head...
Aarhus, Denmark, 6 October 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for neuromuscular disorders, today announces that the first subject has been dosed in a Phase I/IIa clinical trial of NMD670, NMD Pharma’s lead program in development to treat the symptoms of myasthenia gravis (MG). The trial...
– Data to be Presented at the ESMO Virtual Congress 2020 – Melanoma trial (MM1636) shows best-in-class efficacy data in first line melanoma of IO102 and IO103 in combination with nivolumab (anti-PD1 antibody) Copenhagen, Denmark – September 18, 2020: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology,...
Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for neuromuscular disorders, today announces that it has received approval from the Dutch ethics committee and regulatory authorities to advance its development candidate, NMD670, into clinical trials as a novel treatment for the symptoms of myasthenia...
SAN DIEGO and COPENHAGEN, April 22, 2020 /PRNewswire/ — AFYX Therapeutics (“AFYX”), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that its Rivelin® Clobetasol patch (“Rivelin-CLO”) met the primary and multiple secondary endpoints in a Phase 2b study in patients with oral lichen planus (“OLP”). In the largest randomized, double-blind, placebo-controlled...
Data position the company to start potential registrational trials with two drugs in two tumor types Copenhagen, Denmark – February 25, 2020: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of the ongoing Phase 2 trial (IO102-012/KEYNOTE-764) of...
1 2 3

News

Brain stimulation to relieve symptoms of Parkinson’s disease
25. January 2021
Mini-Brains to shed light on nervous disorders
25. January 2021
Mechanisms of schizophrenia
25. January 2021

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge